Vir Biotechnology, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE8-KVir Biotechnology, Inc.VIR5d

   Vir Biotechnology partners with Gilead

   • Collaboration to develop 3 PRO-XTEN TCE candidates for solid tumors
   • $25M equity investment from Gilead at 30% premium
   • Potential $1.74B in milestones and royalties
2. ROUTINE8-KVir Biotechnology, Inc.VIROct 8

   Vir Biotechnology gets FDA Fast Track for VIR-5500

   • FDA granted Fast Track designation to VIR-5500 for late-line mCRPC
   • VIR-5500 is co-developed with Astellas Pharma
   • Phase 3 trials expected to start in 2027
3. ROUTINE3Vir Biotechnology, Inc.VIROct 6

   VIR reports Sawaf Aziz filing

   • Filed by Sawaf Aziz on 10/06/2026
   • Reporting person is EVP, CFO of VIR
   • No beneficial ownership of common stock

   Aziz Sawaf

4. ROUTINE8-KVir Biotechnology, Inc.VIROct 1

   Current report

5. ROUTINE144Vir Biotechnology, Inc.VIRSep 17

   Jason O'Byrne, planned sale of VIR shares

   Jason O'Byrne, reporting

6. ROUTINE144Vir Biotechnology, Inc.VIRSep 9

   Jason O'Byrne, planned sale of VIR shares

   Jason O'Byrne, reporting

7. ROUTINE144Vir Biotechnology, Inc.VIRAug 25

   Jason O'Byrne, planned sale of VIR shares

   Jason O'Byrne, reporting

8. ROUTINE144Vir Biotechnology, Inc.VIRAug 24

   Jason O'Byrne, planned sale of VIR shares

   Jason O'Byrne, reporting

9. ROUTINE144Vir Biotechnology, Inc.VIRAug 21

   Jason O'Byrne, planned sale of VIR shares

   Jason O'Byrne, reporting

10. ROUTINE4Vir Biotechnology, Inc.VIRAug 12

    Robert J More, insider filing for VIR

    Robert J More, reporting

11. ROUTINESCHEDULE 13GVir Biotechnology, Inc.VIRAug 7

    Ownership stake disclosure by STATE STREET CORP

    STATE STREET CORP, filed by

12. NOTABLE10-QVir Biotechnology, Inc.VIRAug 5

    Quarterly report

13. ROUTINE8-KVir Biotechnology, Inc.VIRAug 5

    Current report

14. ROUTINESCHEDULE 13G/AVir Biotechnology, Inc.VIRJul 31

    Ownership stake disclosure by VANGUARD PORTFOLIO MANAGEMENT LLC (amended)

    VANGUARD PORTFOLIO MANAGEMENT LLC, filed by

15. ROUTINE8-KVir Biotechnology, Inc.VIRJul 24

    Current report

16. ROUTINE144Vir Biotechnology, Inc.VIRJun 29

    Saira Ramasastry, planned sale of VIR shares

    Saira Ramasastry, reporting

17. ROUTINE4Vir Biotechnology, Inc.VIRJun 10

    2 insider filings

    Timothy Coughlin, insider filing for VIR

    Show all 2

    • 4Insider filing for VIRJun 10
    • 3New insider at VIRJun 10

    Timothy Coughlin, reporting

18. ROUTINE8-KVir Biotechnology, Inc.VIRJun 10

    Current report

19. ROUTINE4Vir Biotechnology, Inc.VIRJun 2

    2 insider filings

    Janet Napolitano, insider filing for VIR

    Show all 2

    • 4Insider filing for VIRJun 2
    • 4Insider filing for VIRJun 2

    Janet Napolitano, reporting

20. ROUTINE144Vir Biotechnology, Inc.VIRJun 1

    Brent Sabatini, planned sale of VIR shares

    Brent Sabatini, reporting

21. ROUTINE144Vir Biotechnology, Inc.VIRJun 1

    Janet Napolitano, planned sale of VIR shares

    Janet Napolitano, reporting

22. ROUTINE4Vir Biotechnology, Inc.VIRMay 28

    6 insider filings

    Charles Elliott Sigal, insider filing for VIR

    Show all 6

    • 4Insider filing for VIRMay 28
    • 4Insider filing for VIRMay 28
    • 4Insider filing for VIRMay 28
    • 4Insider filing for VIRMay 28
    • 4Insider filing for VIRMay 28
    • 4Insider filing for VIRMay 28

    Charles Elliott Sigal, reporting

23. ROUTINE8-KVir Biotechnology, Inc.VIRMay 28

    Current report

24. ROUTINESCHEDULE 13G/AVir Biotechnology, Inc.VIRMay 15

    Ownership stake disclosure by SB INVESTMENT ADVISERS (UK) LTD (amended)

    SB INVESTMENT ADVISERS (UK) LTD, filed by

25. ROUTINE8-KVir Biotechnology, Inc.VIRMay 6

    Current report

26. ROUTINE4Vir Biotechnology, Inc.VIRMay 4

    Vicki L Sato, insider filing for VIR

    Vicki L Sato, reporting

27. ROUTINE4Vir Biotechnology, Inc.VIRApr 30

    Backer Marianne De, insider filing for VIR

    Backer Marianne De, reporting

28. ROUTINESCHEDULE 13GVir Biotechnology, Inc.VIRApr 29

    Ownership stake disclosure by VANGUARD PORTFOLIO MANAGEMENT LLC

    VANGUARD PORTFOLIO MANAGEMENT LLC, filed by

29. ROUTINEARSVir Biotechnology, Inc.VIRApr 16

    Annual report to shareholders

30. ROUTINEDEFA14AVir Biotechnology, Inc.VIRApr 16

    Additional proxy materials

31. ROUTINEDEF 14AVir Biotechnology, Inc.VIRApr 16

    Proxy statement

32. ROUTINE8-KVir Biotechnology, Inc.VIRApr 10

    Current report

33. ROUTINE4Vir Biotechnology, Inc.VIRApr 7

    Backer Marianne De, insider filing for VIR

    Backer Marianne De, reporting

34. ROUTINE144Vir Biotechnology, Inc.VIRApr 6

    Backer Marianne De, planned sale of VIR shares

    Backer Marianne De, reporting

35. ROUTINE4Vir Biotechnology, Inc.VIRApr 2

    Vicki L Sato, insider filing for VIR

    Vicki L Sato, reporting

36. ROUTINESCHEDULE 13G/AVir Biotechnology, Inc.VIRMar 27

    Ownership stake disclosure by VANGUARD GROUP INC (amended)

    VANGUARD GROUP INC, filed by

37. ROUTINE4Vir Biotechnology, Inc.VIRMar 24

    Brent Sabatini, insider filing for VIR

    Brent Sabatini, reporting

38. ROUTINE4Vir Biotechnology, Inc.VIRMar 23

    Jason O'Byrne, insider filing for VIR

    Jason O'Byrne, reporting

39. ROUTINE144Vir Biotechnology, Inc.VIRMar 23

    Brent Sabatini, planned sale of VIR shares

    Brent Sabatini, reporting

40. ROUTINE8-KVir Biotechnology, Inc.VIRMar 4

    Current report

41. NOTABLESCHEDULE 13D/AVir Biotechnology, Inc.VIRMar 3

    Ownership stake disclosure by ARCH Venture Fund IX, L.P. (amended)

    ARCH Venture Fund IX, L.P., filed by

42. ROUTINE4Vir Biotechnology, Inc.VIRMar 3

    Vicki L Sato, insider filing for VIR

    Vicki L Sato, reporting

43. ROUTINE144Vir Biotechnology, Inc.VIRMar 2

    Vicki L Sato, planned sale of VIR shares

    Vicki L Sato, reporting

Older filings on EDGAR